Hepatitis

Biotech companies sign manufacturing agreement for Belerofon

Published in Drug Week, January 7th, 2005

Nautilus Biotech and Angel Biotechnology announced that they have signed an agreement for the manufacture of Nautilus' improved interferon alpha (Belerofon) for phase I clinical development.

Nautilus has designed and developed an improved, single amino-acid substitution, non-pegylated interferon alpha (Belerofon) with superior biological and pharmacological profile compared to marketed pegylated interferon alpha. Belerofon is a product candidate for a number of indications including chronic hepatits C and cancer. Its improved profile should support lower frequency of administration and lower dosing with higher therapeutic efficacy.

"Nautilus is...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2005-01-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry